Form 8-K - Current report:
SEC Accession No. 0001824293-24-000094
Filing Date
2024-07-26
Accepted
2024-07-26 16:07:43
Documents
18
Period of Report
2024-07-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K val-20240726.htm   iXBRL 8-K 25012
2 EX-5.1 ex51_mintzopinion1.htm EX-5.1 14955
6 GRAPHIC mintzlogo.jpg GRAPHIC 5673
7 GRAPHIC picture1.jpg GRAPHIC 4145
8 GRAPHIC val-20240726_g1.jpg GRAPHIC 16879
9 GRAPHIC val-20240726_g2.jpg GRAPHIC 1656
  Complete submission text file 0001824293-24-000094.txt   215090

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT val-20240726.xsd EX-101.SCH 1913
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT val-20240726_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT val-20240726_pre.xml EX-101.PRE 13590
20 EXTRACTED XBRL INSTANCE DOCUMENT val-20240726_htm.xml XML 2815
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037 (619) 400-1171
GRI BIO, Inc. (Filer) CIK: 0001824293 (see all company filings)

EIN.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40034 | Film No.: 241146882
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)